# A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer

> **NCT01590719** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 123 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Placebo
- **DRUG:** Onartuzumab (MetMAb)
- **DRUG:** Oxaliplatin
- **DRUG:** Folinic acid
- **DRUG:** Levofolinic acid
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT01590719
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2016-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01590719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01590719, "A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01590719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*